Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.63 |
| ▸ | RBP4 | P02753 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086213 | 0.90 | SCD (0.66) | SCDCYP3A4CYP2D6 | |
| SCHEMBL4170432 | 0.89 | TTR (0.61) | SCDCYP3A4CYP2D6TTRRBP4 | |
| SCHEMBL3084640 | 0.89 | SCD (0.63) | SCDCYP3A4CYP2D6 | |
| SCHEMBL4262802 | 0.88 | SCD (0.62) | SCDCYP3A4CYP2D6 | |
| SCHEMBL4252657 | 0.88 | SCD (0.62) | SCDCYP3A4CYP2D6 | |
| SCHEMBL3103939 | 0.87 | SCD (0.61) | SCDCYP3A4CYP2D6 | |
| SCHEMBL1816042 | 0.85 | TTR (0.66) | SCDTTRRBP4 | |
| SCHEMBL4253957 | 0.85 | SCD (0.59) | SCDCYP3A4CYP2D6 | |
| SCHEMBL31162681 | 0.85 | SCD (0.59) | SCDCYP3A4CYP2D6 | |
| SCHEMBL3097261 | 0.85 | SCD (0.59) | SCDCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | claimed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | claimed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | claimed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7799787-B2 | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK FROSST CANADA LTD. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-05-07 | — | — | US | disclosed |
| US-20090088431-A1 | Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. | 2009-04-02 | — | — | US | disclosed |
| EP-1966183-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-09-10 | — | — | EP | disclosed |
| EP-1910352-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| WO-2007071023-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-06-28 | — | — | WO | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | SCD, SCD5, SREBF1 | SCD 1/4885CYP3A4 616/4885CYP2D6 507/4885 |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | SCD 1/4885CYP3A4 978/4885CYP2D6 682/4885 |
| US-20090088431-A1 | Heteroaromatic Compounds as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, SREBF1 | SCD 1/4885CYP3A4 666/4885CYP2D6 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.